The global renal denervation systems market size reached US$ 318 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 2,362 Million by 2028, exhibiting a growth rate (CAGR) of 39.7% during 2022-2028.

Renal denervation (RDN) is an interventional procedure that involves a catheter-based ablation of the sympathetic nerves within the renal artery wall. It maximizes nerve disruption, lowers renin secretion, stimulates natriuresis, and improves renal hemodynamics or blood flow. As a result, RDN systems are extensively used to treat refractory hypertension cases wherein optimal therapy cannot provide relief to the patients.

A significant rise in the prevalence of lifestyle diseases, such as hypertension, on account of the increasing number of individuals who smoke and consume alcohol, rising unhealthy dietary patterns, sedentary and hectic lifestyles, and the growing geriatric population represents, one of the key factors strengthening market growth. Apart from this, the advantages associated with the RDN system, such as fast recovery, safety, time efficiency and cost-effectiveness, are acting as another major growth-inducing factor. Furthermore, the escalating demand for minimally invasive (MI) surgery is also contributing to the growth of the market. The introduction of micro-infusion technology, improving healthcare infrastructure, increasing research and development (R&D) activities and the rising number of filings for regulatory approvals of the systems, are also creating a positive influence on the market growth. Although, a decline in the hospital visits and rescheduling of elective health procedures due to the surging cases of the coronavirus disease (COVID-19) have impacted the market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global renal denervation systems market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, product, technology, application and end user.

Breakup by Product Type:

Catheters
Single Electrode Catheter
Multi Electrode Catheter
RF Generator
Nerve Modifying Agents

Breakup by Product:

Symplicity
Vessix (V2)
EnligHTN
Paradise
Iberis
Others

Breakup by Technology:

Ultrasound Ablation
Radiofrequency Ablation
Microinfusion

Breakup by Application:

Hypertension
Cardiac Disorders
Diabetes
Renal Failure
Others

Breakup by End User:

Diagnostic Centers and Hospitals
Ambulatory Care Centers
Others

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Boston Scientific Group, Kona Medical Inc., Medtronic Plc, Mercator MedSystems, ReCor Medical Inc. (Otsuka Holdings Co. Ltd.), Renal Dynamics, St. Jude Medical Inc. (Abbott) and Terumo Corporation.

Key questions answered in this report:
How has the global renal denervation systems market performed so far and how will it perform in the coming years?
What are the key regional markets?
What has been the impact of COVID-19 on the global renal denervation systems market?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the product?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global renal denervation systems market and who are the key players?
What is the degree of competition in the industry?